We are live on ! Find out more
REGN icon

Regeneron Pharmaceuticals
REGN

1,310 hedge funds and large institutions have $89.2B invested in Regeneron Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 147 funds opening new positions, 481 increasing their positions, 452 reducing their positions, and 95 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 147 | Existing positions closed: 95

10% more capital invested

Capital invested by funds: $81.4B → $89.2B (+$7.84B)

3% more funds holding

Funds holding: 1,273 → 1,310 (+37)

6% more repeat investments, than reductions

Existing positions increased: 481 | Existing positions reduced: 452

0% more funds holding in top 10

Funds holding in top 10: 25 → 25 (0)

0.15% less ownership

Funds ownership: 86.44% → 86.29% (-0.15%)

40% less call options, than puts

Call options by funds: $971M | Put options by funds: $1.63B

Holders
1,310
Holders Change
+37
Holders Change %
+2.91%
% of All Funds
18.87%
Holding in Top 10
25
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.36%
New
147
Increased
481
Reduced
452
Closed
95
Calls
$971M
Puts
$1.63B
Net Calls
-$660M
Net Calls Change
+$17M

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$1.15B
2
JP Morgan Chase
JP Morgan Chase
New York
+$476M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$453M
4
GAA
Global Assets Advisory
Florida
+$335M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$226M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$893M
2
Capital World Investors
Capital World Investors
California
-$452M
3
Holocene Advisors
Holocene Advisors
New York
-$265M
4
Citadel Advisors
Citadel Advisors
Florida
-$196M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$127M
Name Holding Trade Value Shares
Change 		Change in
Stake
SA
1276
Scarborough Advisors
Maryland
$4.81K – – –
RS
1277
Rakuten Securities
Japan
$4.81K +$1.9K +2 +67%
FGAM
1278
Financial Gravity Asset Management
Texas
$4.11K – – –
CTA
1279
Colonial Trust Advisors
South Carolina
$3.85K -$4.75K -5 -56%
CB
1280
CNB Bank
Pennsylvania
$3.85K – – –
FRA
1281
Front Row Advisors
California
$3.85K – – –
HFM
1282
Hartford Financial Management
Connecticut
$3.85K – – –
RWPA
1283
Richard W. Paul & Associates
Michigan
$3.85K – – –
LI
1284
LRI Investments
Florida
$3.85K +$3.8K +4 New
ECM
1285
Everence Capital Management
Indiana
$3.6K – – –
FRA
1286
Frank Rimerman Advisors
California
$2.89K – – –
IHWM
1287
Iron Horse Wealth Management
Iowa
$2.89K – – –
MIM
1288
Macroview Investment Management
Maryland
$1.93K -$6.66K -7 -78%
BONH
1289
Bank of New Hampshire
New Hampshire
$1.93K – – –
CTWM
1290
Cherry Tree Wealth Management
Minnesota
$1.93K – – –
HWP
1291
Highline Wealth Partners
California
$1.93K – – –
HWM
1292
HighMark Wealth Management
Minnesota
$1.93K – – –
LIM
1293
Longfellow Investment Management
Massachusetts
$1.93K – – –
NSIM
1294
North Star Investment Management
Illinois
$1.93K – – –
WA
1295
WestEnd Advisors
North Carolina
$1.93K – – –
TWD
1296
True Wealth Design
Ohio
$1.93K +$951 +1 +100%
ACM
1297
Anfield Capital Management
California
$1.93K +$1.9K +2 New
CIAS
1298
CBIZ Investment Advisory Services
Ohio
$1.93K +$1.9K +2 New
PI
1299
PEAK6 Investments
Illinois
$1.6K +$951 +1 +100%
CAM
1300
ClariVest Asset Management
California
$966 – – –
50 51
52
53 54

REGN Hedge Fund Activity: Q1 2024 in Review

1,310 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2024, worth a combined $89.2B — up 9.6% from $81.4B a quarter earlier.

Buyers outnumbered sellers: 147 funds opened new REGN positions and 95 closed out — a net gain of 52 holders — while 481 added to existing stakes and 452 trimmed.

The largest buyer was Franklin Resources, adding an estimated $1.15B. The largest seller was Morgan Stanley, cutting an estimated $893M.

  • 1,310 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2024, up from 1,273 in Q4 2023.
  • Funds reported $89.2B of Regeneron Pharmaceuticals stock for Q1 2024, up 9.6% quarter-over-quarter.
  • 147 funds opened new Regeneron Pharmaceuticals positions in Q1 2024 and 95 closed out, a net change of +52 holders.
  • The largest Regeneron Pharmaceuticals buyer in Q1 2024 was Franklin Resources, an estimated $1.15B added.
  • The largest Regeneron Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $893M sold.

Based on aggregated 13F filings for Q1 2024.